Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | ELANE | P08246 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.33 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6778071 | 0.77 | KMT2A (0.38) | KMT2ACTSKCTSSCTSLCTSB | |
| SCHEMBL18212488 | 0.68 | KMT2A (0.46) | KMT2ACTSKCTSSCTSLELANE | |
| SCHEMBL28654081 | 0.68 | KMT2A (0.46) | KMT2ACTSKCTSSCTSLELANE | |
| SCHEMBL5435526 | 0.67 | CTSK (0.49) | KMT2ACTSKCTSLCTSBITGB3 | |
| SCHEMBL5451133 | 0.67 | CTSK (0.49) | KMT2ACTSKCTSLCTSBITGB3 | |
| SCHEMBL4766548 | 0.67 | CTSK (0.49) | KMT2ACTSKCTSLCTSBITGB3 | |
| Cyclopentane SCHEMBL28225777 | 0.66 | KMT2A (0.48) | KMT2ACTSKCTSSCTSLCTSB | |
| SCHEMBL9358329 | 0.66 | KMT2A (0.49) | KMT2ACTSKCTSSITGB3ITGA2B | |
| SCHEMBL9358337 | 0.66 | KMT2A (0.49) | KMT2ACTSKCTSSITGB3ITGA2B | |
| SCHEMBL5364563 | 0.65 | ACE (0.55) | KMT2AELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | KMT2A 4314/4885CTSK 556/4885CTSS 594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.